WAY-181187

WAY-181187 is a high-affinity, selective full agonist at the human 5-HT6 receptor (binding affinity around 2.2 nM) developed at Wyeth, and it was characterized alongside a companion agonist, WAY-208466 ^[1]. Its neurochemical signature is distinctive: acute subcutaneous administration significantly and robustly increases extracellular GABA across the frontal cortex, dorsal hippocampus, striatum and amygdala, while producing only modest decreases in cortical dopamine and serotonin and no change in glutamate or noradrenaline at rest ^[1].

Mechanistic experiments showed that these effects are 5-HT6 mediated; the GABA increases were blocked by the antagonist SB-271046, and the downstream catecholamine effects were attenuated by intracortical infusion of the GABA-A antagonist bicuculline, confirming a local 5-HT6 to GABA relationship in the frontal cortex ^[1]. In hippocampal slices the agonist attenuated stimulus-evoked glutamate release, and in the rat schedule-induced polydipsia model of obsessive-compulsive disorder WAY-181187 dose-dependently reduced adjunctive drinking, pointing to anxiolytic and anticompulsive potential ^[1]. In vivo electrophysiology later showed that WAY-181187 dose-dependently increases the firing of serotonin neurons in the dorsal raphe nucleus, an effect opposite to that of the 5-HT6 antagonist SB-399885 and consistent with 5-HT6-mediated positive feedback onto the serotonergic system ^[2].

WAY-181187 is not a therapeutic and was never developed clinically, but it is one of the most important reference 5-HT6 agonists. It embodies the counterintuitive observation that both agonism and antagonism at 5-HT6 can yield cognitive or affective benefits in different paradigms, a puzzle that continues to shape thinking about how the receptor should be targeted ^[1][2].

As a preclinical research compound, WAY-181187 has no human safety data. In rodents it was behaviourally active without notable acute toxicity at studied doses, but it is not intended for human consumption and no clinical tolerability information exists.

WAY-181187 was developed at Wyeth Research in the mid-2000s as part of an effort to define the physiological role of the then newly appreciated 5-HT6 receptor, and it was reported together with WAY-208466. Neither progressed to clinical development, but both became widely used pharmacological tools, and WAY-181187 in particular is a standard agonist reference in 5-HT6 neurochemistry and electrophysiology.

Among 5-HT6 researchers WAY-181187 is a well-known reference agonist, prized for its selectivity and its clear GABA-centric neurochemical fingerprint. It is not a consumer nootropic and is understood strictly as a research chemical, but it is frequently invoked in discussions of why the 5-HT6 receptor resists a simple agonist-or-antagonist framing.